Table 1.
HE4 and CA 125 serum levels in the different studied populations
| Patients (n) | HE4 >150 pmol/L | Median±SE (pmol/L) | Range (pmol/L) | 95 percentile (pmol/L) | CA 125 >35 U/mL | Median±SE (U/mL) | Range (U/mL) | 95 percentile (U/mL) | ROMA | Patients risk | 95 percentile | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Healthy female | 66 | 1 (1.5%) | 54.7 ± 4.1 | 13.9–184 | 123 | 9 (13.6%) | 15 ± 1.4 | 5–49 | 45.7 | 10.4 + 1.5 | 17 (25.8%) | 38.9 |
| Premenopausal | 34 | 1 (2.9%) | 52.7 ± 6.5 | 13.9–184 | 138.3 | 9 (26.5%)* | 18 ± 2.4 | 7–49 | 46.8 | 8.7 + 2.5 | 15 (44.1%) | 46.8 |
| Postmenopausal | 32 | 0 (0%) | 58.5 ± 4.9 | 24.9–149 | 132 | 0 (0%)* | 12 ± 1.2 | 5–32 | 28.8 | 11.5 + 1.5 | 2 (6.3%) | 33.4 |
| Benign gynaecological diseases** | 285 | 3 (1.1%) | 46.5 ± 1.5 | 4.6–220.9 | 100.3 | 86 (30.2%) | 21 ± 2.2 | 5–319 | 94.6 | 6.8 + 0.5 | 35 (12.3%) | 29.6 |
| Premenopausal | 226 | 0 (0%) | 44.1 + 1.1 | 4.6–220.9 | 77.6 | 73 (32.3%) | 22 + 2.7 | 5–319 | 104 | 5.8 + 0.4 | 25 (11.5%) | 19.2 |
| Postmenopausal | 59 | 3 (5.1%) | 64.2 + 4.5 | 22.3–199.6 | 157.7 | 13 (22%) | 15 + 3.2 | 5–145 | 81 | 13.6 + 1.5 | 10 (16.9%) | 45 |
| Endometriosis | 68 | 0 (0%) | 43.4 + 1.6 | 19.8 + 85.8 | 76.2 | 30 (44.1%) | 31 + 3.5 | 5–1,148 | 106.2 | 5.5 + 0.6 | 7 (10.3%) | 19 |
| Myomas | 56 | 0 (0%) | 48.6 + 3 | 4.6–118 | 99.4 | 21 (37.5%) | 26 + 7 | 7–319 | 134 | 7.4 + 1.1 | 7 (12.5%) | 29.8 |
| Cysts | 137 | 3 (2.2%) | 46 + 2.4 | 19–199.6 | 113.8 | 32 (23.3%) | 18 + 3.1 | 5–317 | 92.9 | 7.2 + 0.9 | 16 (11.7%) | 35.6 |
| Others | 24 | 0 (0%) | 53.8 + 3.5 | 33.3–111 | 107 | 3 (12.5%) | 13.5 + 3.2 | 5–67 | 62.5 | 7.5 + 1.7 | 5 (20.8%) | 33.8 |
| NED | 33 | 3 (9.1%) | 96 + 8.7 | 24.3–251 | 218.1 | 4 (12.1%) | 12 + 3.2 | 3–87 | 73.7 | 15 + 2.7 | 12 (36.4%) | 53.1 |
| Ovarian cancer** | 111 | 88 (79.3%) | 406 + 79.3*** | 17.2–7341 | 1,801 | 92 (82.9%) | 185 ± 118.2 | 2–8,630 | 2,720.6 | 85.7 + 2.7 | 100 (90.1%) | 99.6 |
| Endometrial cancer | 17 | 6 (35.3%) | 124.5 ± 1.4*** | 33.7–503.6 | 503.6 | 14 (82.4%) | 165 ± 49.2 | 8–652 | 652 | 66.1 + 6 | 16 (94.1%) | 92.9 |
| Endocervical cancer | 7 | 2 (28.6%) | 85 + 29.8*** | 16.1–208 | 208 | 4 (57.2%) | 49 + 1,160 | 5–8,340 | 8,340 | 57.3 + 11.7 | 5 (71.4%) | 77.1 |
| Squamous Cervical cancer | 8 | 0 (0%) | 103.1 ± 3.2*** | 38.5–126 | 126 | 2 (25%) | 26 ± 77.7 | 13–649 | 649 | 27.5 + 9.4 | 5 (62.5%) | 83.7 |
ROMA Risk of Ovarian Malignancy Algorithm
*p = 0.005; **p = 0.001; ***p = 0.001